Sven Guenther - Zevra Therapeutics Chief Officer
| ZVRA Stock | 9.49 0.10 1.04% |
Executive
Sven Guenther is Chief Officer of Zevra Therapeutics
| Age | 52 |
| Address | 1180 Celebration Boulevard, Celebration, FL, United States, 34747 |
| Phone | 321 939 3416 |
| Web | https://zevra.com |
Zevra Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3281) % which means that it has lost $0.3281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3067) %, meaning that it created substantial loss on money invested by shareholders. Zevra Therapeutics' management efficiency ratios could be used to measure how well Zevra Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.49. In addition to that, Return On Capital Employed is expected to decline to -0.53. At present, Zevra Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 89.7 M, whereas Other Assets are forecasted to decline to about 468.8 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael JD | Foghorn Therapeutics | 59 | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| Mr MBA | C4 Therapeutics | 46 | |
| Stefan Abele | Pharvaris BV | 54 | |
| Christopher Nasveschuk | C4 Therapeutics | N/A | |
| MD MBA | Molecular Partners AG | N/A | |
| Suresh Silva | Shattuck Labs | N/A | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Conor CPA | Shattuck Labs | N/A | |
| An Song | 4D Molecular Therapeutics | N/A | |
| FAAAAI FAAP | 4D Molecular Therapeutics | 63 | |
| Calais Pharm | Transcode Therapeutics | 65 | |
| Crystal Zuckerman | Pmv Pharmaceuticals | N/A | |
| Douglas MBA | Akebia Ther | 63 | |
| Courtney Solberg | C4 Therapeutics | N/A | |
| Samuel Berry | Fortress Biotech | N/A | |
| Gregory Fuest | Passage Bio | N/A | |
| Mayra ReyesArmour | C4 Therapeutics | N/A | |
| Erik MBA | Akebia Ther | 52 | |
| Steven MD | Akebia Ther | 63 | |
Management Performance
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.33 |
Zevra Therapeutics Leadership Team
Elected by the shareholders, the Zevra Therapeutics' board of directors comprises two types of representatives: Zevra Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zevra. The board's role is to monitor Zevra Therapeutics' management team and ensure that shareholders' interests are well served. Zevra Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zevra Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christal MA, CoFounder Officer | ||
| Joshua MBA, Executive Officer | ||
| Sven Guenther, Chief Officer | ||
| Christopher Lauderback, Senior Manufacturing | ||
| Daniel Gallo, Senior Advocacy | ||
| LaDuane CPA, Secretary, CFO | ||
| Rene Braeckman, Senior Development | ||
| MD FFPM, Chief Officer | ||
| Rahsaan JD, Secretary Officer | ||
| Alison Peters, Chief Officer | ||
| Nichol Ochsner, Vice Communications | ||
| Neil McFarlane, CEO President |
Zevra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zevra Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (7.39) % | ||||
| Current Valuation | 482.16 M | ||||
| Shares Outstanding | 53.38 M | ||||
| Shares Owned By Insiders | 6.61 % | ||||
| Shares Owned By Institutions | 54.60 % | ||||
| Number Of Shares Shorted | 3.94 M | ||||
| Price To Book | 7.33 X | ||||
| Price To Sales | 20.89 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zevra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zevra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zevra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zevra Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.13) | Revenue Per Share 0.575 | Quarterly Revenue Growth 0.276 | Return On Assets (0.33) | Return On Equity (1.31) |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.